We are working to advance

Cytoprotective Therapies

Learn More

CMX-2043 Ischemix

Lead Product Candidate

Learn more
Ischemix Market Opportunity

Market Opportunity

Learn more
Ischemix Clinical Trials

Clinical Trials

Learn more

Developing Novel Cytoprotective Drugs

Prevention and Treatment of Serious Diseases

Ischemix is a privately-held, clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems. Ischemix’ lead product candidate, CMX-2043, is in a Phase 2 trial for prevention of contrast-induced acute kidney injury and periprocedural cardiac injury. This breakthrough cytoprotective agent activates endogenous pathways of cell survival, enabling vital organs to survive acute challenges that can occur during medical treatment or hospitalization, including invasive cardiovascular procedures, serious infections and agents such as diagnostic contrast media. There are currently no drugs approved for these indications.

Learn more

Hospital-Acquired Acute Kidney Injury

A Serious and Growing Problem in Hospitals Worldwide

Hospital-acquired acute kidney injury (HA-AKI) is associated with increased morbidity, mortality and health care resource consumption. This injury is estimated to afflict approximately three million patients and cause 700,000 deaths worldwide every year. In the US, at least 1.8 million hospitalized patients are diagnosed annually with HA-AKI at a cost of at least $10 billion. The incidence of this injury progressing to renal failure and kidney dialysis has recently been increasing at 10% per year. Ischemix’ first target within the overall HA-AKI population is patients at risk of contrast-induced acute kidney injury (CI-AKI).

Learn more

Periprocedural Cardiac Injury

Despite advances in technology and pharmacology, injury to the heart arising during therapeutic cardiac catheterization (also called PCI or “stenting”) and coronary artery bypass surgery (CABG) is a significant problem. There are approximately 600,000 PCIs and 400,000 CABG procedures in the US each year. Up to 16% of PCI patients, depending on the type of procedure being performed, are estimated to sustain a myocardial infarction (MI) during the procedure. As many as 20% of CABG patients suffer short- and long-term complications, including MIs. In a previous, successful Phase 2 trial, CMX-2043 demonstrated the ability to significantly reduce cardiac injury in PCI patients.

Learn more